Ventricular arrhythmia. Paroxysmal tachycardia
Conditions
Interventions
Intervention 1: Intervention group: Taking pentoxifylline 400 mg tablets three times a day for 3 months. Intervention 2: Control group: Taking placebo tablets, which look exactly like 400 mg pentoxify
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age older than 18 years old Heart failure diagnosis ICD implantation > 6 months before eligibility test Signed written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Using Pentoxifylline or other methyl Methylxanthines New York Heart Association Class IV heart failure Renal dysfunction with eGFR < 30 Hepatic dysfunction Body mass index < 18.5 kg/m2 Pregnant or suspected pregnancy Patients with the following events within 3months before the eligibility test: alteration of antiarrhythmic drug, catheter ablation for ventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization, heart failure requiring hospitalization Other comorbidities including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer ICDs unable to record cardiac arrhythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of the ventricular arrhythmias (PVC, NSVT, VT, VF). Timepoint: The beginning of the study and 3 months later. Method of measurement: ICD (implantable cardioverter-defibrillator) record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization. Timepoint: The beginning of the study and 3 months later. Method of measurement: Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Zahra Zandi
Mashhad University of Medical Sciences
Outcome results
None listed